Existing research demonstrates that obsessive-compulsive disorder (OCD) is a multifactorial condition that is influenced by genetics and environmental risk factors. First-line treatment of OCD is typically a combination of an antidepressant medication and cognitive behavioral therapy. However, SSRI treatments for OCD yields benefit to approximately only 40-60% of patients and has been found to cause adverse side effects. There has been an emerging interest in the use of nutritional and plant-based interventions to treat OCD, including N-acetylcysteine, inositol, and probiotics. This webinar will discuss the research evaluating its clinical utility, and how to incorporate adjuvant therapies to minimize medication side effects while enhancing treatment outcomes.
James M. Greenblatt, M.D. is Chief Medical Officer at Walden, where he oversees eating disorder programs in Massachusetts and Connecticut. He is board-certified in child and adult psychiatry. In addition, Dr. Greenblatt is a clinical faculty member in the psychiatry departments at Tufts Medical School and the Geisel School of Medicine at Dartmouth College. He is the author of six books: Answers to Anorexia (2011), The Breakthrough Depression Solution (2012), Answers to Binge Eating (2014), Integrative Therapies for Depression: Redefining Models for Assessment, Treatment, and Prevention (2015), Nutritional Lithium: The Cinderella Story (2016), and The Breakthrough Depression Solution 2nd eds. (2016). His latest book, Finally Focused, describing integrative therapies for ADHD, will be available Spring 2017 (www.finallyfocusedbook.com).
CLICK HERE TO SIGN UP